Skip to main content

Table 3 Overall treatment duration in the Safety population (N = 32)

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

 

Months of treatment

 
 

< 4

4

> 4

Total

No. of patients

3

14

15

32

Median duration (range) (in days)

65 (56–94)

121 (105–130)

214 (138–258)

129.5 (56–258)

Mean duration ± SD (in days)

71.7 ± 19.9

120.1 ± 7.1

200.9 ± 46.4

153.5 ± 57.1